Biocon's API Facility Passes US FDA Inspection with Two Observations

Biocon Ltd, a prominent player in the pharmaceutical industry, has recently undergone a GMP surveillance inspection by the U.S. Food and Drug Administration (US FDA) at its API facility in Visakhapatnam, Andhra Pradesh. The inspection took place between 3rd and 7th November, 2025. Although two observations were cited at the end of the inspection, the company is confident that these will be addressed within the stipulated time and there will be no significant impact on the business.